CPRX - カタリスト・ファ―マシュ―ティカルズ (Catalyst Pharmaceuticals Inc.) カタリスト・ファ―マシュ―ティカルズ

 CPRXのチャート


 CPRXの企業情報

symbol CPRx
会社名 Catalyst Pharmaceuticals Inc (カタリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カタリスト・ファーマシューティカル(Catalyst Pharmaceuticals Inc. )(旧名:Catalyst Pharmaceutical Partners Inc.)は、開発段階のバイオ医薬品会社である。同社は、希少な衰弱性疾患を患うの人々のための治療法の開発及び商品化に注力する。同社には、「Firdapse」、「CPP-109」及び「CPP-115」の3品目の開発中の薬剤がある。「Firdapse」は、ランバート摂食筋萎縮症候群(LEMS)及び先天性筋無力症候群(CMS)の治療に適応され、amifampridineのリン酸塩から構成される。「Firdapse」の第Ⅲ相試験は完了した。「CPP-109」は、γ-アミノ酪酸(GABA)アミノトランスフェラーゼ阻害剤であり、トゥレット症候群の治療に適応される。「CPP-115」は、GABAアミノトランスフェラーゼ阻害剤であり、複雑な部分発作、トゥレット症候群及びてんかん発作などの神経学的適応症の治療に適応される。   カタリスト・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。神経筋と神経疾患をタ―ゲットとして処方薬の開発と商業化に従事。筋力低下を特徴とする自己免疫疾患であるランバ―ト・イ―トン症候群の治療薬Firdapse、乳児けいれんの治療薬CPP-115、トゥレット症候群治療CPP-109の開発を行う。本社はフロリダ州。   
本社所在地 355 Alhambra Circle Suite 1250 Coral Gables FL 33134 USA
代表者氏名 Patrick James McEnany パトリック・ジェームス・マッケナニー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 305-529-2522
設立年月日 38899
市場名 NASDAQ Small Cap
ipoyear 2006年
従業員数 21人
url www.catalystpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cprx
adr_tso
EBITDA EBITDA(百万ドル) -22.05182
終値(lastsale) 3.39
時価総額(marketcap) 347811484.62
時価総額 時価総額(百万ドル) 339.60350
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 271.19460
当期純利益 当期純利益(百万ドル) -21.23038
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $11.7M. Higher net loss reflects reasear increase of 32% to $6.4M (expense) General and administrative - Balancing increase of 57% to $4.1M (expense) Stock-based Compensation in SGA increase of 23% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.11.

 CPRXのテクニカル分析


 CPRXのニュース

   Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold  2020/11/03 15:18:45 InvestorPlace
Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.
   Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020  2020/11/02 13:03:00 GlobeNewswire
CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical…
   Analysts Anticipate Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Will Post Quarterly Sales of $31.22 Million  2020/10/20 18:02:47 Transcript Daily
Equities research analysts expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report $31.22 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $32.57 million and the lowest estimate coming in at $29.84 million. Catalyst Pharmaceuticals […]
   Catalyst Pharmaceutical Stock Got Caught in the Crossfire  2020/10/20 09:01:13 InvestorPlace
Although Catalyst Pharmaceuticals stock scored a major clinical victory, politics and competition got in the way of a viable buy case.
   ROCE Insights For Catalyst Pharmaceuticals  2020/08/14 10:30:00 Benzinga
Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 …
   Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold  2020/11/03 15:18:45 InvestorPlace
Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.
   Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020  2020/11/02 13:03:00 GlobeNewswire
CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical…
   Analysts Anticipate Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Will Post Quarterly Sales of $31.22 Million  2020/10/20 18:02:47 Transcript Daily
Equities research analysts expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report $31.22 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $32.57 million and the lowest estimate coming in at $29.84 million. Catalyst Pharmaceuticals […]
   Catalyst Pharmaceutical Stock Got Caught in the Crossfire  2020/10/20 09:01:13 InvestorPlace
Although Catalyst Pharmaceuticals stock scored a major clinical victory, politics and competition got in the way of a viable buy case.
   ROCE Insights For Catalyst Pharmaceuticals  2020/08/14 10:30:00 Benzinga
Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 …
   Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold  2020/11/03 15:18:45 InvestorPlace
Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk.
   Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020  2020/11/02 13:03:00 GlobeNewswire
CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical…
   Analysts Anticipate Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Will Post Quarterly Sales of $31.22 Million  2020/10/20 18:02:47 Transcript Daily
Equities research analysts expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report $31.22 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $32.57 million and the lowest estimate coming in at $29.84 million. Catalyst Pharmaceuticals […]
   Catalyst Pharmaceutical Stock Got Caught in the Crossfire  2020/10/20 09:01:13 InvestorPlace
Although Catalyst Pharmaceuticals stock scored a major clinical victory, politics and competition got in the way of a viable buy case.
   ROCE Insights For Catalyst Pharmaceuticals  2020/08/14 10:30:00 Benzinga
Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カタリスト・ファ―マシュ―ティカルズ CPRX Catalyst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)